The Effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy – MONARCH 2: A randomized clinical trial - Sledge, GW; Toi, M; Neven, P (JAMA Oncol, 2020)
et al.